Pharmacological Institute, College of Medicine, National Taiwan University, Taipei, Taiwan.
Cancer Lett. 2010 Jun 28;292(2):163-70. doi: 10.1016/j.canlet.2009.11.020. Epub 2009 Dec 28.
Attacking angiogenesis is considered an effective strategy for controls the expansion and metastasis of tumors and other related-diseases. The aim of this study was to assess the effects of moscatilin, a bibenzyl derivative, on VEGF and bFGF-induced angiogenesis in cultured human umbilical vein endothelial cells (HUVECs) in vitro and in vivo. Moscatilin significantly inhibited growth of lung cancer cell line A549 (NSCLC) and suppressed growth factor-induced neovascularization. In addition, VEGF- and bFGF-induced cell proliferation, migration, and tube formation of HUVECs was markedly inhibited by moscatilin. Western blotting analysis of cell signaling molecules indicated that moscatilin inhibited ERK1/2, Akt, and eNOS signaling pathways in HUVECs. These results suggest that inhibition of angiogenesis by moscatilin may be a major mechanism in cancer therapy.
抗血管生成被认为是控制肿瘤和其他相关疾病的扩张和转移的有效策略。本研究旨在评估莫斯卡汀(一种联苯苄衍生物)对体外和体内培养的人脐静脉内皮细胞(HUVEC)中 VEGF 和 bFGF 诱导的血管生成的影响。莫斯卡汀显著抑制肺癌细胞系 A549(非小细胞肺癌)的生长,并抑制生长因子诱导的新血管生成。此外,莫斯卡汀明显抑制 VEGF 和 bFGF 诱导的 HUVEC 细胞增殖、迁移和管形成。细胞信号分子的 Western 印迹分析表明,莫斯卡汀抑制了 HUVEC 中的 ERK1/2、Akt 和 eNOS 信号通路。这些结果表明,莫斯卡汀抑制血管生成可能是癌症治疗的主要机制。